A machine learning model that predicts heart-failure readmission with an AUC of 0.89 sounds impressive—until a clinician asks which variables drove the prediction and where they came from. If the answer is a 400-column spreadsheet with names like lab_0427_mean and no documented lineage, the model won't survive contact with a hospital committee, let alone a regulator.
This is the gap an evidence-linked pipeline closes. It's not a new algorithm. It's a discipline: every engineered feature traces back to raw source data, a documented transformation, and a clinical rationale grounded in guidelines or published research. This article walks through how to build one for heart failure, from clinical definitions to deployment considerations.
Heart failure affects roughly 6.2 million adults in the United States, according to the CDC. It was mentioned on 379,800 death certificates in 2018 alone. The American Heart Association projects prevalence will climb from 2.4% of the population in 2012 to 3.0% by 2030—more than 8 million adults.
Those numbers translate into a specific data problem. HF patients generate enormous volumes of longitudinal data: serial lab draws, repeated echocardiograms, medication titrations, device interrogations, and frequent hospitalizations. A single HF admission in a critical care database can span thousands of timestamped events. The signal is there. Extracting it is the hard part.
Raw EHR data is not model-ready. A creatinine value of 1.8 mg/dL is a number. Whether it represents acute kidney injury, chronic kidney disease, or a transient blip depends on the patient's baseline, the trajectory over the preceding days, and the clinical context. Feature engineering is the step that converts those raw numbers into variables that carry meaning.
Systematic reviews of machine learning models for HF prediction report AUCs from 0.70 to 0.90—a range wide enough to suggest that feature choices, not just algorithm choices, drive performance. The same gradient boosting library applied to a well-engineered feature set and a raw dump of columns will produce very different results.
An evidence-linked pipeline has three commitments:
This isn't bureaucracy for its own sake. It's what makes a model auditable, debuggable, and defensible when someone asks why a patient was flagged as high-risk.
Key Takeaway: Feature engineering isn't preprocessing busywork. In HF modeling, it's where clinical knowledge enters the pipeline—and where most of the performance difference between models actually lives.
Heart failure is a clinical syndrome, not a single disease. The standard definition: symptoms and signs resulting from any structural or functional cardiac disorder that impairs the ventricle's ability to fill with or eject blood (Yancy et al., Circulation, 2013).
Two things it is not. First, HF does not mean the heart has stopped—that's cardiac arrest, a different entity. Second, HF is not synonymous with "weak heart." Roughly half of HF patients have preserved ejection fraction, meaning the heart pumps normally by that metric but still fails to meet the body's demands, typically because of impaired relaxation or elevated filling pressures.
Ejection fraction (EF) is the percentage of blood ejected from the left ventricle per beat. It anchors the modern classification:
This matters for feature engineering because the phenotypes have different risk factors, different comorbidities, and different prognostic features. A model trained on HFrEF patients and applied to HFpEF patients will underperform. Natriuretic peptide thresholds, for instance, are set higher for diagnosing HFpEF in some guidelines precisely because the biology differs.
The New York Heart Association class describes symptom severity:
NYHA class is a feature in itself, but it's also a trap. It's assigned by clinicians, often inconsistently, and it's frequently missing from structured EHR fields—buried in narrative notes instead. When you do extract it, document the source. A NYHA class pulled from a discharge summary carries different reliability than one recorded in a structured intake form.
The AHA, ESC, and HFSA publish diagnostic criteria that should inform feature definitions. The 2013 ACCF/AHA guideline (Yancy et al.) remains a foundational reference, and subsequent ESC and AHA/HFSA updates refine thresholds. When you define a feature like "elevated BNP," cite the threshold you used and its source. Guidelines differ—some use BNP > 100 pg/mL, others use age-stratified NT-proBNP cutoffs. The choice affects who gets labeled as a case.
Key Takeaway: HF is a syndrome with distinct phenotypes. Feature sets should be phenotype-aware, and any threshold-based feature (BNP, EF, NYHA) should cite the guideline it follows.
Feature engineering covers three operations:
A creatinine value is extraction. Converting it from µmol/L to mg/dL is transformation. Computing the ratio of creatinine at admission to baseline is construction.
Most tabular HF models use static features: one row per patient, one column per variable. That discards the temporal structure that makes HF data rich.
Temporal features capture three things:
A patient whose BNP drops from 2,000 to 800 over 48 hours is clinically different from one whose BNP sits at 800 throughout—even though the "latest BNP" feature is identical. Temporal engineering recovers that distinction.
| Family | Examples |
|---|---|
| Demographics | Age, sex, race/ethnicity |
| Vitals | Heart rate, blood pressure, respiratory rate, SpO2 |
| Labs | BNP, NT-proBNP, creatinine, sodium, potassium, hemoglobin |
| Comorbidities | Diabetes, hypertension, CKD, atrial fibrillation, COPD |
| Medications | Beta-blockers, ACE inhibitors/ARBs, loop diuretics, MRAs |
| Imaging | LVEF, left atrial volume index, E/e' ratio, LV end-diastolic volume |
Each family has its own data quality profile. Labs are timestamped and numeric but irregularly sampled. Comorbidities are coded, but code-based definitions have variable positive predictive values. Medications are recorded but often as free-text or non-standardized names.
Adding features increases the risk of overfitting, especially with small cohorts. A model with 500 features trained on 1,000 patients will find spurious correlations. Feature selection isn't optional—it's a requirement.
There's also a subtler problem: correlated features inflate apparent importance. If you include both BNP and NT-proBNP, both will appear important, and interpretation becomes muddy. Clinically redundant features crowd out genuinely informative ones.
Key Takeaway: More features mean more overfitting risk, more maintenance burden, and more interpretation problems. Build features with a reason, then select ruthlessly.
MIMIC-III and MIMIC-IV are the workhorses of critical care ML research, freely available on PhysioNet. MIMIC-III contains de-identified data for over 40,000 ICU patients (Johnson et al., Scientific Data, 2016), and heart failure is among the most common primary diagnoses, with over 10,000 admissions.
MIMIC's strength is granularity: timestamped vitals, labs, medications, and notes. Its weakness is the same as any EHR-derived dataset—missing data, irregular sampling, and code-based diagnoses that require validation.
The Framingham Heart Study and the Multi-Ethnic Study of Atherosclerosis (MESA) have driven much of what we know about HF risk factors. Framingham identified hypertension, diabetes, and obesity as major risk factors with population attributable risks of 39%, 12%, and 8% respectively (Levy et al., NEJM, 2002).
These cohorts are smaller than EHR datasets but have the advantage of prospective, protocol-driven measurement. They're ideal for validating that an engineered feature behaves the way clinical theory predicts before you deploy it on messier data.
Echocardiographic parameters—LVEF, left atrial volume index, E/e'—are central to HF classification. Some datasets store these as structured fields; others bury them in narrative reports. Extracting them reliably often requires NLP, and the extraction method becomes part of the feature's provenance.
Consumer and implantable devices generate continuous heart rate, activity, and sometimes intracardiac pressure data. This is the frontier for HF decompensation prediction, but the data is noisy, sampling rates vary, and regulatory acceptance is still developing. Treat sensor-derived features as a distinct provenance class with its own validation requirements.
Key Takeaway: Different data sources have different reliability profiles. Document which source each feature comes from, because it affects how much you can trust the model's output.
Define your cohort with explicit, reproducible criteria. ICD-9/ICD-10 codes are the standard starting point, but code-based HF definitions have variable positive predictive values. A common approach is to require a primary HF diagnosis code plus corroborating evidence—elevated BNP, echocardiographic findings, or HF-specific medication orders.
Document every inclusion and exclusion criterion. "Patients with HF" is not a cohort definition; "adults with a primary ICD-10 I50.x code and at least one BNP measurement > 100 pg/mL during admission" is.
Missing data in HF datasets is rarely random. BNP isn't measured in patients who look well. Creatinine is measured more often in patients with known kidney disease. This is missingness by indication, and it carries information.
Options include:
Whichever you choose, document it. The imputation method is part of the feature's provenance.
This is where domain knowledge earns its keep. Examples:
Each of these should have a one-line rationale in your feature documentation. "BNP slope: captures treatment response and trajectory, supported by [citation]."
Three families of methods exist:
In practice, combine them. Use filter methods to prune obvious noise, embedded methods to rank, and clinical judgment to override when a statistically weak feature is clinically essential.
Train with cross-validation, validate on a held-out set, and—critically—link every feature in the final model back to its source and rationale. If a feature's importance is high but its provenance is unclear, that's a red flag, not a discovery.
Key Takeaway: The pipeline is a chain of documented decisions. Each step—cohort definition, imputation, construction, selection—should be reproducible from the written record alone.
NT-proBNP has a sensitivity of roughly 90% and specificity of 70–80% for diagnosing acute HF in patients presenting with dyspnea (Januzzi et al., PRIDE study, American Journal of Cardiology, 2005). That makes it one of the strongest single features available.
But the raw value is only the start. Useful derived features include:
Each captures a different clinical question. Discharge BNP predicts readmission; peak BNP reflects severity; slope reflects treatment response.
LVEF is the anchor, but it's a coarse measure. Additional features include:
These require reliable extraction from echo reports, which often means NLP. Document the extraction method—it affects reproducibility.
Heart rate variability, blood pressure swings, and weight changes (from daily weights in HF admissions) are all temporal features with clinical rationale. A 2 kg weight gain over 48 hours is a classic HF decompensation signal. Encoding it as a feature requires computing the difference between consecutive measurements and handling irregular sampling intervals.
Comorbidity flags from ICD codes are standard but imperfect. A validated approach: use the Charlson or Elixhauser comorbidity indices, which have published code mappings and validation studies. For medications, map free-text names to a standard vocabulary (RxNorm, ATC) before creating binary flags.
Key Takeaway: The best features combine a strong clinical signal with a reliable extraction method. A clinically important feature that's extracted unreliably will hurt more than help.
Regulatory bodies—the FDA in the US, the EU's MDR framework—increasingly expect documentation of how AI/ML medical tools were developed. Reproducibility isn't just a scientific norm; it's a compliance requirement. A model whose features can't be traced to source data can't be audited, and an unauditable model won't be approved.
There's also a practical debugging benefit. When a model fails on a subgroup, traceability lets you ask: is the failure in the feature extraction, the feature itself, or the model? Without provenance, you're guessing.
For each feature, record:
A simple YAML or JSON schema can capture this. The point is that it exists and is version-controlled alongside the code.
Key Takeaway: Traceability is both a scientific requirement and a regulatory one. Build it into the pipeline from day one—retrofitting it is painful.
"Heart failure means the heart stops." No. It means the heart can't meet demand. Cardiac arrest is a different event.
"More features are always better." No. More features mean more overfitting, more noise, and more maintenance. Selection is essential.
"ML replaces clinicians." No. ML models flag risk; clinicians make decisions. The model's job is to surface information that might otherwise be missed, not to practice medicine.
An engineered feature that improves AUC in a retrospective dataset isn't validated. It needs prospective testing, subgroup analysis, and ideally comparison to existing clinical scores. The gap between retrospective performance and prospective utility is where most models fail.
Key Takeaway: The most dangerous misconception is that a good AUC means a good model. Clinical validation is a separate, necessary step.
Convolutional neural networks can learn features directly from ECG waveforms and echocardiogram images, bypassing manual extraction. This is powerful but demanding: it requires large labeled datasets, and the learned features are harder to interpret. Hybrid approaches—using deep learning for extraction and traditional models for prediction—are gaining traction.
The most promising direction is combining EHR data, imaging, and sensor streams into a unified feature set. Each modality captures different aspects of HF physiology. The engineering challenge is aligning them temporally and handling their different sampling rates and reliability profiles.
Feature engineering and explainability are complementary. A model built on well-documented, clinically meaningful features is inherently more explainable than one built on opaque embeddings. As regulatory expectations tighten, this will become a competitive advantage, not just a nice-to-have.
An evidence-linked pipeline isn't a single tool. It's a set of practices: document provenance, justify features clinically, version everything, and validate before deploying.
The payoff is a model that clinicians can interrogate, regulators can audit, and researchers can reproduce. In a field where the data is messy, the phenotypes are heterogeneous, and the stakes are high, that's not optional.
Key Takeaway: Build features with reasons. Document where they come from. Validate what they claim. The rest follows.
What is the goal of feature engineering in heart failure research? To transform raw clinical, imaging, and sensor data into variables that carry clinical meaning and improve predictive model performance. Raw values often lack context; engineered features add it.
Why is an evidence-linked pipeline important? It ensures every feature can be traced to its source and rationale, making models reproducible, auditable, and defensible. It also aids debugging when models fail.
What are common data sources for heart failure feature engineering? EHRs (MIMIC-III, MIMIC-IV), registries and cohort studies (Framingham, MESA), echocardiography reports, and wearable sensor data.
How are features selected in heart failure machine learning models? Filter methods (correlation, mutual information), wrapper methods (recursive feature elimination), and embedded methods (LASSO, tree importance), often combined with clinical judgment.
What is the role of biomarkers like BNP in feature engineering? BNP and NT-proBNP are among the strongest single features for HF diagnosis and prognosis. Derived features—slope, peak, discharge value—add temporal information.
Can deep learning automatically engineer features for heart failure? Yes, particularly for ECG and echocardiogram images. But it requires large labeled datasets, and the learned features are harder to interpret than manually engineered ones.
What are the challenges in heart failure feature engineering? Missing data, phenotype heterogeneity, class imbalance, irregular temporal sampling, and the gap between retrospective performance and prospective utility.
How does the MIMIC database support heart failure research? MIMIC-III and MIMIC-IV provide de-identified, timestamped ICU data with granular labs, vitals, and medications. HF is one of the most common diagnoses in these datasets.
What is the difference between HFrEF and HFpEF in terms of features? HFrEF (LVEF ≤ 40%) and HFpEF (LVEF ≥ 50%) have different risk factors, comorbidities, and prognostic features. BNP thresholds and echocardiographic parameters differ between them.
Are there standard guidelines for heart failure feature definitions? Yes. The AHA/ACC, ESC, and HFSA publish diagnostic criteria and classification systems that should inform feature definitions. Cite the guideline version you follow.
Ready to build your own evidence-linked pipeline? Explore the MIMIC database on PhysioNet, review the current AHA/ESC guidelines, and start engineering features with clinical traceability from the first commit.